PIK3CA and neoplasm: Alpelisib (BYL719) is an FDA-approved isiPI3K [30] that binds the p110 alpha subunit of PI3K and is inducing tumor growth arrest in PIK3CA altered solid cancers, including in HNCHPV− [23,29,31,32,33].